Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor tyrosine-protein kinase erbB-2 extracellular domain IV (HER2 ECD IV) is a membrane-proximal subdomain of the human epidermal growth factor receptor 2 (HER2/ErbB-2). Unlike other members of the epidermal growth factor receptor family, HER2 has no known ligand and exists in a constitutively active conformation, making it the preferred partner for heterodimerization with other ErbB receptors. Subdomain IV plays a critical structural role in facilitating ligand-independent homodimerization and stabilizing active signaling complexes. Overexpression or amplification of HER2 is a well-established oncogenic driver in approximately 15-30% of breast and gastric cancers, leading to hyperactivation of downstream cell proliferation and survival pathways.
HER2 ECD IV is the primary therapeutic target for the landmark monoclonal antibody trastuzumab, as well as next-generation antibody-drug conjugates (ADCs) like trastuzumab emtansine and trastuzumab deruxtecan. Binding of therapeutic agents to this domain sterically hinders receptor dimerization, prevents the proteolytic shedding of the extracellular domain (which would otherwise leave an active p95HER2 fragment), and flags the cancer cells for destruction via antibody-dependent cellular cytotoxicity (ADCC). Despite its clinical success, targeting this domain is associated with notable safety concerns, most significantly cardiotoxicity and interstitial lung disease, as well as therapeutic challenges such as resistance mediated by epitope masking or bypass pathway activation.
Monoclonal antibodies and antibody-drug conjugates bind specifically to subdomain IV of the HER2 extracellular domain. This binding inhibits ligand-independent HER2 homodimerization and downstream signaling pathways (such as PI3K-AKT-mTOR and RAS-RAF-MEK-ERK), prevents proteolytic shedding of the extracellular domain, and recruits immune effector cells to induce antibody-dependent cellular cytotoxicity (ADCC). For antibody-drug conjugates, binding also facilitates receptor-mediated endocytosis and lysosomal degradation, releasing cytotoxic payloads directly into the target tumor cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor tyrosine-protein kinase erbB-2 extracellular domain IV (HER2 ECD IV).